Haleon Bilan de santé

Santé financière contrôle des critères 2/6

Haleon possède un total de capitaux propres de £16.7B et une dette totale de £9.1B, ce qui porte son ratio d'endettement à 54.2%. Son actif total et son passif total sont £33.4B et de £16.7B. L'EBIT de Haleon est £2.5B ce qui fait que son ratio de couverture des intérêts 6.9. Elle dispose de liquidités et de placements à court terme de £531.0M.

Informations clés

54.2%

Ratio d'endettement

UK£9.05b

Dette

Ratio de couverture des intérêts	6.9x
Argent liquide	UK£531.00m
Fonds propres	UK£16.71b
Total du passif	UK£16.69b
Total des actifs	UK£33.40b

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de HLN ( £4.7B ) ne couvrent pas ses passifs à court terme ( £5.6B ).

Passif à long terme: Les actifs à court terme de HLN ( £4.7B ) ne couvrent pas ses passifs à long terme ( £11.1B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de HLN ( 51% ) est considéré comme élevé.

Réduire la dette: Données insuffisantes pour déterminer si le ratio d'endettement de HLN a diminué au cours des 5 dernières années.

Couverture de la dette: La dette de HLN est bien couverte par le flux de trésorerie opérationnel ( 24.2% ).

Couverture des intérêts: Les paiements d'intérêts de HLN sur sa dette sont bien couverts par l'EBIT ( 6.9 x couverture).

Haleon Bilan de santé

Santé financière contrôle des critères 2/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Haleon: Tailwinds Are Mostly Priced In

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 455,701,825 shares, representing 4.99% of its issued share capital., under the authorization approved on May 8, 2024.

Pfizer Intends to Sell About 540 Million Ordinary Shares in Haleon

Dr. Reddy'S Laboratories S.A. completed the acquisition of Northstar Switzerland SARL from Haleon plc (LSE:HLN).

Haleon Announces the Launch of Eroxon®?, the First and Only Fda Cleared Otc Gel for Erectile Dysfunction, Available for U.S. Pre Order Without A Prescription

Haleon: Defensive Consumer Healthcare Stock As Safe Haven

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 913,000,000 shares, representing 10% of its issued share capital, under the authorization approved on May 8, 2024.

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 913,000,000 shares, representing 10% of its issued share capital, under the authorization approved on May 8, 2024.

Haleon plc Provides Earnings Guidance for the Fiscal Year 2024

Haleon plc to Report Fiscal Year 2024 Results on Mar 05, 2025

Dr. Reddy'S Laboratories S.A. signed a definitive agreement to acquire Northstar Switzerland SARL from Haleon plc (LSE:HLN) for £500 million.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Haleon plc Announces Directorate Change

Haleon plc Announces Chief Financial Officer Changes

Haleon plc has filed a Follow-on Equity Offering.

Haleon plc has filed a Follow-on Equity Offering.

Haleon plc has filed a Follow-on Equity Offering.

Sensodyne Introduces New Triple Action Formula: 'Sensitivity Gum & Enamel'

Haleon plc, Annual General Meeting, May 08, 2024

Haleon plc Proposes Final Dividend for Fiscal Year 2023, Payable on 16 May 2024

Dr Reddy's Laboratories Reportedly Eyes Mega Brand in UK

The Investment Case For Haleon: Steady Shareholder Value Accumulation

Haleon plc to Report Fiscal Year 2023 Results on Feb 29, 2024

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

The Share Price Has The Flu, But Haleon Is As Healthy As An Ox

Haleon plc Provides Earnings Guidance for the Fiscal Year 2023

Haleon Reportedly Exploring Sale of Nicotine Gum Business

Haleon: A Hidden Gem In The Consumer Health Market

Haleon exploring sale of ChapStick Brand - report

Haleon plc Announces Board Changes

Haleon said to evaluate potential deals to increase its size - report

Haleon plc Provides Revenue Guidance for Fiscal 2022

Haleon plc Provides Revenue Guidance for Fiscal 2022

Haleon: Undervalued With Clear Catalyst Ahead

Former GSK consumer health unit Haleon hits all-time low

Haleon Introduces Advil PLUS Acetaminophen to Canadians, Combining Two Trusted Pain Relievers into One Convenient Tablet

Haleon plc to Report First Half, 2022 Results on Sep 19, 2022

Haleon CEO says brand recognition, gross margins will drive growth - CNBC

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines